{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:50:01Z","timestamp":1788573001095,"version":"build-2803163510"},"reference-count":106,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"unspecified","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,2,10]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, offering durable responses and prolonged survival. However, these therapies also present unique challenges, particularly with the onset of immune-related adverse events (irAEs), which can manifest during treatment either acutely and\/or become chronic or emerge long after treatment cessation. Delayed, chronic, and re-emergent irAEs often require tailored survivorship care, including coordination across multiple disciplines focused on oncology, specialty care, and primary care. Despite the increased usage of ICIs, there is limited longitudinal data guiding the surveillance, diagnosis, attribution, and management of irAEs after ICI treatment. To address these gaps, the Society for Immunotherapy of Cancer convened an Expert Panel to deliberate best practices and identify research opportunities for improving post-treatment care. This paper outlines these expert insights into irAE surveillance, coordination and continuity across care transitions and settings, and clinical management strategies. The paper also underscores the importance of clinicians\u2019 understanding of irAE onset patterns, multidisciplinary coordination, and the urgent need in the field for the development of a comprehensive irAE registry. By addressing these critical gaps, the oncology community can better support the growing population of ICI-treated cancer survivors, ensuring improved quality of life and care outcomes.<\/jats:p>","DOI":"10.1136\/jitc-2025-012823","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T13:15:32Z","timestamp":1772543732000},"page":"e012823","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term data"],"prefix":"10.1136","volume":"14","author":[{"given":"Tessa F","family":"Flores","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Cancer Survivorship and Screening, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA"},{"name":"Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily S","family":"Tonorezos","sequence":"additional","affiliation":[{"name":"Office of Cancer Survivorship, National Cancer Institute Division of Cancer Control and Population Sciences, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3816-2238","authenticated-orcid":false,"given":"Shailender","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology-Oncology, University of Washington and Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie R","family":"Brahmer","sequence":"additional","affiliation":[{"name":"Department of Oncology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2795-7059","authenticated-orcid":false,"given":"Laura C","family":"Cappelli","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Cooper","sequence":"additional","affiliation":[{"name":"ImmunoOncology Branch, Developmental Therapy Program, National Cancer Institute Division of Cancer Treatment and Diagnosis, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Davies","sequence":"additional","affiliation":[{"name":"Smilow Cancer Hospital at Yale-New Haven, Yale Cancer Center, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Guild","sequence":"additional","affiliation":[{"name":"AIM at Melanoma, Sacramento, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Gunturu","sequence":"additional","affiliation":[{"name":"Hartford HealthCare Cancer Institute, Hartford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5884-7704","authenticated-orcid":false,"given":"John B A G","family":"Haanen","sequence":"additional","affiliation":[{"name":"Netherlands Cancer Institute, Amsterdam, The Netherlands"},{"name":"Leiden University Medical Center, Leiden, The Netherlands"},{"name":"Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario E","family":"Lacouture","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dermatology Division, NYU Grossman Long Island School of Medicine, Mineola, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0788-7938","authenticated-orcid":false,"given":"Rom","family":"Leidner","sequence":"additional","affiliation":[{"name":"EACRI, Providence Cancer Institute, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Outcomes Research Branch, National Cancer Institute Healthcare Delivery Research Program, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9537-9038","authenticated-orcid":false,"given":"Dennis G","family":"Moledina","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Nephrology, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javid","family":"Moslehi","sequence":"additional","affiliation":[{"name":"Section of Cardio-Oncology and Immunology, Cardiovascular Research Institute, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3470-8686","authenticated-orcid":false,"given":"Jarushka","family":"Naidoo","sequence":"additional","affiliation":[{"name":"Department of Oncology, Beaumont Hospital, Dublin, Leinster, Ireland"},{"name":"RCSI University of Medicine and Health Sciences, Dublin, Leinster, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2095-2677","authenticated-orcid":false,"given":"Michel","family":"Obeid","sequence":"additional","affiliation":[{"name":"Department of Medicine, LCIT center, Service of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3367-7961","authenticated-orcid":false,"given":"Michael","family":"Postow","sequence":"additional","affiliation":[{"name":"Melanoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9803-3497","authenticated-orcid":false,"given":"Igor","family":"Puzanov","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E","family":"Reid","sequence":"additional","affiliation":[{"name":"Cancer Screening and Survivorship, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca D","family":"Santomasso","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Department of Neurology, Weill Cornell Medical College, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3524-7858","authenticated-orcid":false,"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Comprehensive Cancer Cancer Center (Westdeutsches Tumorzentrum), University Hospital Essen, Essen, Germany"},{"name":"National Center for Tumor Diseases (NCT-West), Essen, Germany"},{"name":"Research Alliance Ruhr, Research Center One Health, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3877-3984","authenticated-orcid":false,"given":"Ann W","family":"Silk","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5344-6645","authenticated-orcid":false,"given":"Ryan J","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Walunas","sequence":"additional","affiliation":[{"name":"Center for Health Information Partnerships, Institute for Artificial Intelligence in Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5148-6130","authenticated-orcid":false,"given":"Yinghong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-475X","authenticated-orcid":false,"given":"Paolo A","family":"Ascierto","sequence":"additional","affiliation":[{"name":"Department of Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy"},{"name":"Universit\u00e0 degli studi di Napoli Federico II, Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8132-7069","authenticated-orcid":false,"given":"Marc S","family":"Ernstoff","sequence":"additional","affiliation":[{"name":"Section of Oncology, Dartmouth Health, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"2026090204552708000_14.3.e012823.1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1595"},{"key":"2026090204552708000_14.3.e012823.2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2026090204552708000_14.3.e012823.3","first-page":"579","article-title":"Immune checkpoint inhibitor therapy in oncology: current uses and future directions: JACC: cardiooncology state-of-the-art review","volume":"4","author":"Tan","year":"2022","journal-title":"Cardio Oncology"},{"key":"2026090204552708000_14.3.e012823.4","doi-asserted-by":"crossref","first-page":"114146","DOI":"10.1016\/j.ejca.2024.114146","article-title":"Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinoma","volume":"207","author":"Luke","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026090204552708000_14.3.e012823.5","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1002\/ijc.35347","article-title":"How many people in the US are eligible for and respond to checkpoint inhibitors: An empirical analysis","volume":"156","author":"Haslam","year":"2025","journal-title":"Intl Journal of Cancer"},{"key":"2026090204552708000_14.3.e012823.6","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.210"},{"key":"2026090204552708000_14.3.e012823.7","unstructured":"Clinicaltrials.gov."},{"key":"2026090204552708000_14.3.e012823.8","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab223"},{"key":"2026090204552708000_14.3.e012823.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2407417"},{"key":"2026090204552708000_14.3.e012823.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2330"},{"key":"2026090204552708000_14.3.e012823.11","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3390\/cancers15030600","article-title":"Neoadjuvant Immune Checkpoint Inhibitors for Resectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis","volume":"15","author":"Zhao","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026090204552708000_14.3.e012823.12","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.575472","article-title":"Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients With Early-Stage Non-small Cell Lung Cancer","volume":"10","author":"Bai","year":"2020","journal-title":"Front Oncol"},{"key":"2026090204552708000_14.3.e012823.13","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/CCO.0000000000000675","article-title":"Integrating immunotherapy in the (neo)adjuvant setting of early breast cancer","volume":"32","author":"Chan","year":"2020","journal-title":"Curr Opin Oncol"},{"key":"2026090204552708000_14.3.e012823.14","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11041038","article-title":"Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis","volume":"11","author":"Rizzo","year":"2022","journal-title":"J Clin Med"},{"key":"2026090204552708000_14.3.e012823.15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40259-022-00525-x","article-title":"Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing","volume":"36","author":"van Akkooi","year":"2022","journal-title":"BioDrugs"},{"key":"2026090204552708000_14.3.e012823.16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15153833","article-title":"Neoadjuvant Immunotherapy for Patients with dMMR\/MSI-High Gastrointestinal Cancers: A Changing Paradigm","volume":"15","author":"Ozer","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026090204552708000_14.3.e012823.17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15164114","article-title":"The Present and Future of Neoadjuvant and Adjuvant Therapy for Locally Advanced Gastric Cancer","volume":"15","author":"Koerner","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026090204552708000_14.3.e012823.18","doi-asserted-by":"crossref","first-page":"9513","DOI":"10.1007\/s00432-023-04749-4","article-title":"Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC","volume":"149","author":"Walia","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026090204552708000_14.3.e012823.19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejca.2020.05.005","article-title":"Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand","volume":"135","author":"Patrinely","year":"2020","journal-title":"Eur J Cancer"},{"key":"2026090204552708000_14.3.e012823.20","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00600-w"},{"key":"2026090204552708000_14.3.e012823.21","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.annonc.2021.03.204","article-title":"Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma","volume":"32","author":"Owen","year":"2021","journal-title":"Ann Oncol"},{"key":"2026090204552708000_14.3.e012823.22","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.27145","article-title":"Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected Melanoma","volume":"6","author":"Goodman","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026090204552708000_14.3.e012823.23","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0645-6","article-title":"Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance","volume":"7","author":"Couey","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026090204552708000_14.3.e012823.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00484-3"},{"key":"2026090204552708000_14.3.e012823.25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006398","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology","volume":"11","author":"Naidoo","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026090204552708000_14.3.e012823.26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.049981"},{"key":"2026090204552708000_14.3.e012823.27","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007307","article-title":"Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer","volume":"11","author":"Drobni","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026090204552708000_14.3.e012823.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109970"},{"key":"2026090204552708000_14.3.e012823.29","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jaccao.2022.09.005","article-title":"LAG3 Regulates T Cell Activation and Plaque Infiltration in Atherosclerotic Mice","volume":"4","author":"Mulholland","year":"2022","journal-title":"JACC CardioOncol"},{"key":"2026090204552708000_14.3.e012823.30","unstructured":"NICE . NICE real-world evidence framework. 2022."},{"key":"2026090204552708000_14.3.e012823.31","unstructured":"Administration USFD . Framework for FDA\u2019s Real-World Evidence Program. 2018."},{"key":"2026090204552708000_14.3.e012823.32","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70039","article-title":"Defining concepts in cancer survivorship","volume":"131","author":"Mollica","year":"2025","journal-title":"Cancer"},{"key":"2026090204552708000_14.3.e012823.33","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s11764-024-01618-y","article-title":"Correction: Developing national cancer survivorship standards to inform quality of care in the United States using a consensus approach","volume":"18","author":"Mollica","year":"2024","journal-title":"J Cancer Surviv"},{"key":"2026090204552708000_14.3.e012823.34","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0367"},{"key":"2026090204552708000_14.3.e012823.35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00662.x"},{"key":"2026090204552708000_14.3.e012823.36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2010.00923.x"},{"key":"2026090204552708000_14.3.e012823.37","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.adro.2018.08.018","article-title":"Role of the immunosuppressive microenvironment in immunotherapy","volume":"3","author":"Tormoen","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"2026090204552708000_14.3.e012823.38","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003743","article-title":"Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067","volume":"9","author":"Regan","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026090204552708000_14.3.e012823.39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.7609"},{"key":"2026090204552708000_14.3.e012823.40","first-page":"A595","article-title":"526 Pharmacokinetic and pharmacodynamic analyses of PD-1 blockade with nivolumab at varying doses and schedules supports administration at markedly reduced dose and frequency","volume":"12","author":"Tachiki","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026090204552708000_14.3.e012823.41","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026090204552708000_14.3.e012823.42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"2026090204552708000_14.3.e012823.43","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/imr.13270","article-title":"The evolving landscape of immune-related adverse events that follow immune checkpoint immunotherapy in cancer patients","volume":"318","author":"Villani","year":"2023","journal-title":"Immunol Rev"},{"key":"2026090204552708000_14.3.e012823.44","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(95)90125-6"},{"key":"2026090204552708000_14.3.e012823.45","doi-asserted-by":"publisher","DOI":"10.1126\/science.270.5238.985"},{"key":"2026090204552708000_14.3.e012823.46","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80089-8"},{"key":"2026090204552708000_14.3.e012823.47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0307252101"},{"key":"2026090204552708000_14.3.e012823.48","doi-asserted-by":"publisher","DOI":"10.1126\/science.272.5260.405"},{"key":"2026090204552708000_14.3.e012823.49","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090847"},{"key":"2026090204552708000_14.3.e012823.50","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0856"},{"key":"2026090204552708000_14.3.e012823.51","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","article-title":"T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis","volume":"611","author":"Axelrod","year":"2022","journal-title":"Nature New Biol"},{"key":"2026090204552708000_14.3.e012823.52","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308541"},{"key":"2026090204552708000_14.3.e012823.53","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature01621","article-title":"Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease","volume":"423","author":"Ueda","year":"2003","journal-title":"Nature New Biol"},{"key":"2026090204552708000_14.3.e012823.54","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jfma.2020.04.004","article-title":"The PD-1\/PD-L pathway in rheumatic diseases","volume":"120","author":"Zhang","year":"2021","journal-title":"J Formos Med Assoc"},{"key":"2026090204552708000_14.3.e012823.55","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4321"},{"key":"2026090204552708000_14.3.e012823.56","doi-asserted-by":"publisher","DOI":"10.1038\/nri724"},{"key":"2026090204552708000_14.3.e012823.57","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026090204552708000_14.3.e012823.58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214"},{"key":"2026090204552708000_14.3.e012823.59","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"2026090204552708000_14.3.e012823.60","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.15_suppl.2505"},{"key":"2026090204552708000_14.3.e012823.61","doi-asserted-by":"crossref","unstructured":"Singh S , Long JP , Tchakarov A , et al . Tertiary lymphoid structure signatures are associated with immune checkpoint inhibitor related acute interstitial nephritis. JCI Insight 2022.:e165108. doi:10.1172\/jci.insight.165108","DOI":"10.1172\/jci.insight.165108"},{"key":"2026090204552708000_14.3.e012823.62","doi-asserted-by":"crossref","DOI":"10.1172\/JCI180583","article-title":"Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis","volume":"134","author":"Moledina","year":"2024","journal-title":"J Clin Invest"},{"key":"2026090204552708000_14.3.e012823.63","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1077468","article-title":"Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives","volume":"13","author":"Liu","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026090204552708000_14.3.e012823.64","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026090204552708000_14.3.e012823.65","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/jamacardio.2021.2241","article-title":"Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis: A Narrative Review","volume":"6","author":"Lehmann","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026090204552708000_14.3.e012823.66","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1159\/000491599","article-title":"Neurosarcoidosis following Immune Checkpoint Inhibition","volume":"11","author":"Dunn-Pirio","year":"2018","journal-title":"Case Rep Oncol"},{"key":"2026090204552708000_14.3.e012823.67","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0390-2"},{"key":"2026090204552708000_14.3.e012823.68","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008591","article-title":"Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update","volume":"12","author":"Fletcher","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026090204552708000_14.3.e012823.69","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0837"},{"key":"2026090204552708000_14.3.e012823.70","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1001\/jamaoncol.2021.0051","article-title":"Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma","volume":"7","author":"Patrinely","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026090204552708000_14.3.e012823.71","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0823"},{"key":"2026090204552708000_14.3.e012823.72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.09.033"},{"key":"2026090204552708000_14.3.e012823.73","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1738382"},{"key":"2026090204552708000_14.3.e012823.74","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2021.03.010","article-title":"Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy","volume":"149","author":"Ghisoni","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026090204552708000_14.3.e012823.75","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006500","article-title":"Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review","volume":"11","author":"Barron","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026090204552708000_14.3.e012823.76","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejca.2020.04.025","article-title":"Late immune-related adverse events in long-term responders to PD-1\/PD-L1 checkpoint inhibitors: A multicentre study","volume":"134","author":"Nigro","year":"2020","journal-title":"Eur J Cancer"},{"key":"2026090204552708000_14.3.e012823.77","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.1389"},{"key":"2026090204552708000_14.3.e012823.78","doi-asserted-by":"crossref","unstructured":"Tapiavala S , Shenouda MA , Patel VG , et al . Reporting of immune-related adverse events (irAEs) in US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. American Society of Clinical Oncology; 2024.","DOI":"10.3389\/fonc.2025.1606599"},{"key":"2026090204552708000_14.3.e012823.79","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/eurheartj\/ehab430","article-title":"Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy","volume":"43","author":"Michel","year":"2022","journal-title":"Eur Heart J"},{"key":"2026090204552708000_14.3.e012823.80","doi-asserted-by":"crossref","first-page":"405","DOI":"10.12998\/wjcc.v7.i4.405","article-title":"Immune checkpoint inhibitor-induced colitis: A comprehensive review","volume":"7","author":"Som","year":"2019","journal-title":"WJCC"},{"key":"2026090204552708000_14.3.e012823.81","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223885"},{"key":"2026090204552708000_14.3.e012823.82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.12.008"},{"key":"2026090204552708000_14.3.e012823.83","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaccao.2022.11.011","article-title":"Atherosclerosis With Immune Checkpoint Inhibitor Therapy: Evidence, Diagnosis, and Management: JACC: CardioOncology State-of-the-Art Review","volume":"4","author":"Suero-Abreu","year":"2022","journal-title":"JACC CardioOncol"},{"key":"2026090204552708000_14.3.e012823.84","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252011049","article-title":"Immune Checkpoint Inhibitor Therapy and Associations with Clonal Hematopoiesis","volume":"25","author":"Singh","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026090204552708000_14.3.e012823.85","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/NCC.0000000000001012","article-title":"Evaluation of a Nurse-Led Patient Navigation Intervention: Follow-Up of Patients After Autologous and Allogeneic Stem Cell Transplantation","volume":"45","author":"van der Lans","year":"2022","journal-title":"Cancer Nurs"},{"key":"2026090204552708000_14.3.e012823.86","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1188\/11.CJON.33-40","article-title":"Oncology nurse navigator","volume":"15","author":"Case","year":"2011","journal-title":"Clin J Oncol Nurs"},{"key":"2026090204552708000_14.3.e012823.87","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-021-01128-1"},{"key":"2026090204552708000_14.3.e012823.88","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1089\/tmj.2021.0531","article-title":"Use of Asynchronous Interprofessional e-Consults in Cancer Patients During the COVID-19 Pandemic: Current and Future Role","volume":"29","author":"Gordon","year":"2023","journal-title":"Telemed J E Health"},{"key":"2026090204552708000_14.3.e012823.89","unstructured":"(CDC) UCfDCaP . ICD-10-cm. 2024. Available: https:\/\/www.cdc.gov\/nchs\/icd\/icd-10-cm\/index.html"},{"key":"2026090204552708000_14.3.e012823.90","first-page":"61","article-title":"Patient-Reported Outcomes (PROs) and Patient-Reported Outcome Measures (PROMs)","volume":"6","author":"Weldring","year":"2013","journal-title":"Health Serv Insights"},{"key":"2026090204552708000_14.3.e012823.91","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.04.007"},{"key":"2026090204552708000_14.3.e012823.92","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.10.005"},{"key":"2026090204552708000_14.3.e012823.93","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/jnci\/djab171","article-title":"Meta-Analysis of Quality of Life in Cancer Patients Treated With Immune Checkpoint Inhibitors","volume":"114","author":"Gonzalez","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"2026090204552708000_14.3.e012823.94","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s11764-023-01507-w","article-title":"Survivorship outcomes in patients treated with immune checkpoint inhibitors: a scoping review","volume":"19","author":"G\u00fcven","year":"2025","journal-title":"J Cancer Surviv"},{"key":"2026090204552708000_14.3.e012823.95","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2022.08.029","article-title":"Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients\u2019 health-related quality of life","volume":"176","author":"Schulz","year":"2022","journal-title":"Eur J Cancer"},{"key":"2026090204552708000_14.3.e012823.96","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.387","article-title":"Progresses in biomarkers for cancer immunotherapy","volume":"4","author":"Lin","year":"2023","journal-title":"MedComm (2020)"},{"key":"2026090204552708000_14.3.e012823.97","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1331959","article-title":"Rapid identification of inflammatory arthritis and associated adverse events following immune checkpoint therapy: a machine learning approach","volume":"15","author":"Tran","year":"2024","journal-title":"Front Immunol"},{"key":"2026090204552708000_14.3.e012823.98","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.24.00326","article-title":"Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease Codes in Patient Records","volume":"42","author":"Sun","year":"2024","journal-title":"JCO"},{"key":"2026090204552708000_14.3.e012823.99","doi-asserted-by":"crossref","DOI":"10.1186\/s12911-021-01564-0","article-title":"Electronic patient-reported outcomes and machine learning in predicting immune-related adverse events of immune checkpoint inhibitor therapies","volume":"21","author":"Iivanainen","year":"2021","journal-title":"BMC Med Inform Decis Mak"},{"key":"2026090204552708000_14.3.e012823.100","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-2655"},{"key":"2026090204552708000_14.3.e012823.101","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1158\/0008-5472.CAN-23-2468","article-title":"NCI Cancer Research Data Commons: Resources to Share Key Cancer Data","volume":"84","author":"Wang","year":"2024","journal-title":"Cancer Res"},{"key":"2026090204552708000_14.3.e012823.102","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-2657"},{"key":"2026090204552708000_14.3.e012823.103","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-2730"},{"key":"2026090204552708000_14.3.e012823.104","doi-asserted-by":"publisher","DOI":"10.1093\/jamia\/ocu023"},{"key":"2026090204552708000_14.3.e012823.105","doi-asserted-by":"publisher","DOI":"10.1136\/amiajnl-2011-000376"},{"key":"2026090204552708000_14.3.e012823.106","doi-asserted-by":"crossref","first-page":"113505","DOI":"10.1016\/j.ejca.2023.113505","article-title":"The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects","volume":"199","author":"Ertl","year":"2024","journal-title":"Eur J Cancer"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-012823","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:55:53Z","timestamp":1788350153000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-012823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":106,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,3]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/jitc-2025-012823"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-012823","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}